NCT01471691已完成1 期
Phase I/II, Open-label, Study of Intravitreal RAnibizumab 0.5MG, or High Dose 1.0mg for Retinal Vein Occlusions With rEfractory Macular Edema Previously Receiving iNtravitreal Bevacizumab (RAVEN)
Hanscom, Thomas, M.D.2 个研究点 分布在 1 个国家目标入组 14 人开始时间: 2011年11月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 14
- 试验地点
- 2
- 主要终点
- Mean Change From Baseline BCVA
研究概览
简要总结
This study examines two doses of Ranibizumab (0.5mg and 1.0mg) for the treatment of macular edema secondary to retinal vein occlusion in patients that have previously failed treatment with other macular edema treatments including bevacizumab.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Ability to provide written informed consent and comply with study assessments for the full duration of the study
- •Age > 18 years
- •CRVO or BRVO diagnosis
- •For CRVO, clinical evidence of perfused central retinal vein occlusion. A CRVO is defined as an eye that has retinal hemorrhages and a dilated retinal venous system in all 4 quadrants. Other evidence of a CRVO may include telangiectatic capillary bed and collateral vessels at the optic nerve head.
- •Central macular edema present on clinical examination and OCT testing with a central point thickness and/or central 1mm subfield thickness > 300 microns after at least 3 months of bevacizumab or steroid therapy.
- •Visual acuity score greater than or equal to 19 letters (20/400) and less than or equal to 73 letters (20/40) by the ETDRS visual acuity protocol.
- •Patients must demonstrate that they are no longer improving on bevacizumab or intravitreal steroid therapy (i.e. no improvement in acuity in 2 consecutive visits)
- •BRVO patients treated with grid laser must show residual edema three months following latest laser treatment
- •Media clarity, pupillary dilation and patient cooperation sufficient to allow OCT testing and retinal photography
排除标准
- •Pregnancy (positive pregnancy test) or known to be pregnant; also pre-menopausal women not using adequate contraception.
- •Participation in another ocular investigation or trial simultaneously
- •Any condition that, in the opinion of the investigator, would preclude participation in the study (e.g. chronic alcoholism, drug abuse)
- •Significant diabetic retinopathy (greater than moderate NPDR) or macular edema associated with diabetic retinopathy
- •An eye that, in the investigator's opinion, has no chance of improving in visual acuity following resolution of macular edema (e.g. presence of subretinal fibrosis or geographic atrophy or severe epiretinal membrane)
- •Presence of another ocular condition that may affect the visual acuity or macular edema during the course of the study (e.g. AMD, uveitis, Irvine-Gas)
- •Evidence of neovascularization of the iris or retina (presence of ischemic CRVO/BRVO)
- •Evidence of central atrophy or fibrosis in the study eye
- •Presence of substantial cataract, one that might decrease the vision by 3 or more lines of vision at sometime during the study.
- •History of grid/focal laser or panretinal laser in the study eye in the previous three months
- •History of vitreous surgery in the study eye
- •History of use of intravitreal, peribulbar, or retrobulbar steroids within three months of the study.
- •History of cataract surgery within 6 months of enrollment.
- •History of YAG capsulotomy within 2 months of the surgery.
- •Visual acuity <20/400 in the fellow eye
- •Uncontrolled glaucoma (pressure >30) despite treatment with glaucoma medications.
- •History of cerebral vascular accident or myocardial infarction within 3 months prior to Day 0.
研究组 & 干预措施
intravitreal ranibizumab 0.5mg
Experimental
干预措施: ranibizumab 0.5mg (Drug)
intravitreal ranibizumab 1.0mg
Experimental
干预措施: ranibizumab 1.0mg (Drug)
结局指标
主要结局
Mean Change From Baseline BCVA
时间窗: Baseline to month 6
Vision was measured using a standard ETDRS chart at baseline and each subsequent monthly visit.
次要结局
- Mean Change From Baseline in Center Point Thickness(months 1-12)
- Change in Mean Best Corrected Visual Acuity From Baseline(months 1-12)
- Percentage of Patients With CFT Less Than 300um(Month 6 and 12)
- Excess Foveal Thickness(Month 6 and 12)
- Total Number of Ranibizumab Injections(month 12)
研究者
研究点 (2)
Loading locations...
相似试验
终止
2 期
Intravitreal Ranibizumab to Treat Macular Edema After Panretinal Photocoagulation (Phase II)Macular EdemaProliferative Diabetic RetinopathyNCT00668785Jumper, J. Michael, M.D.6
已完成
2 期
Safety and Efficacy of Ranibizumab in Diabetic Macular Edema With Center InvolvementDiabetic Macular EdemaNCT00284050Novartis151
进行中（未招募）
1 期
Macular Edema Ranibizumab v. Intravitreal anti-inflammatory Therapy (MERIT) TrialEUCTR2017-003243-37-GBMUST Coordinating Centre, John Hopkins Bloomberg School of Public Health240
已完成
1 期
Ranibizumab 0.5mg and 2.0mg to Treat Diabetic Macular Edema in Patients With Poor Response to BevacizumabDiabetic Macular EdemaNCT01292798California Retina Consultants43
Unknown
1 期
Ranibizumab For Persistent Diabetic Macular Edema After BevacizumabDiabetic Macular EdemaNCT01845844Southeast Retina Center, Georgia30